CY1111946T1 - To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας - Google Patents

To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας

Info

Publication number
CY1111946T1
CY1111946T1 CY20111100032T CY111100032T CY1111946T1 CY 1111946 T1 CY1111946 T1 CY 1111946T1 CY 20111100032 T CY20111100032 T CY 20111100032T CY 111100032 T CY111100032 T CY 111100032T CY 1111946 T1 CY1111946 T1 CY 1111946T1
Authority
CY
Cyprus
Prior art keywords
pyridinyl
dichloro
heptane
diazodicyclo
analgesic agent
Prior art date
Application number
CY20111100032T
Other languages
English (en)
Inventor
Michael J Buckley
Jianquo JI
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1111946T1 publication Critical patent/CY1111946T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση αποκαλύπτει το (1S,5S) -3- (5,6-διχλωρο-3-πυριδινυλο) -3, 6-διαζαδικύκλο[3.2.0]επτάνιο και τη χρήση του στην αντιμετώπιση του πόνου και άλλων διαταραχών που συνδέονται με το νικοτινικό υποδοχέα της ακετυλοχολίνης.
CY20111100032T 2003-05-27 2011-01-11 To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας CY1111946T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/445,555 US20040242641A1 (en) 2003-05-27 2003-05-27 (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
EP04752844A EP1626973B1 (en) 2003-05-27 2004-05-20 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent

Publications (1)

Publication Number Publication Date
CY1111946T1 true CY1111946T1 (el) 2015-11-04

Family

ID=33450880

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100032T CY1111946T1 (el) 2003-05-27 2011-01-11 To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας

Country Status (22)

Country Link
US (1) US20040242641A1 (el)
EP (1) EP1626973B1 (el)
JP (1) JP4716999B2 (el)
KR (2) KR20060015738A (el)
CN (1) CN1826344B (el)
AT (1) ATE485296T1 (el)
AU (1) AU2004243270B2 (el)
BR (1) BRPI0410808A (el)
CA (1) CA2526530C (el)
CY (1) CY1111946T1 (el)
DE (1) DE602004029671D1 (el)
DK (1) DK1626973T3 (el)
ES (1) ES2352199T3 (el)
HK (1) HK1092135A1 (el)
MX (1) MXPA05012738A (el)
NZ (2) NZ588123A (el)
PL (1) PL1626973T3 (el)
PT (1) PT1626973E (el)
SI (1) SI1626973T1 (el)
TW (1) TWI332502B (el)
WO (1) WO2004106342A1 (el)
ZA (1) ZA200509601B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7354937B2 (en) * 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8222278B2 (en) * 2008-06-03 2012-07-17 Abbott Laboratories Treatment of attention-deficit/hyperactivity disorder
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
JP5759470B2 (ja) 2009-10-23 2015-08-05 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての二置換オクタヒドロピロロ［３，４−ｃ］ピロール
EP2491034B1 (en) * 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
WO2011090669A1 (en) * 2010-01-20 2011-07-28 Abbott Laboratories Methods for treating pain
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
KR102559922B1 (ko) 2016-03-10 2023-07-25 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
EP1147112B1 (en) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
CN1348449A (zh) * 1999-04-26 2002-05-08 神经研究公司 杂芳基二氮杂环烷烃及其制备方法和应用
HU225894B1 (en) * 1999-05-21 2007-12-28 Abbott Lab Heterocyclic substituted aminoazacycles useful as central nervous system agents
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents

Also Published As

Publication number Publication date
NZ588123A (en) 2012-04-27
JP2007500220A (ja) 2007-01-11
ATE485296T1 (de) 2010-11-15
ZA200509601B (en) 2006-10-25
CA2526530A1 (en) 2004-12-09
AU2004243270A1 (en) 2004-12-09
BRPI0410808A (pt) 2006-06-27
KR20060015738A (ko) 2006-02-20
CN1826344B (zh) 2013-03-06
AU2004243270B2 (en) 2009-12-17
DK1626973T3 (da) 2011-01-10
KR101238281B1 (ko) 2013-03-04
SI1626973T1 (sl) 2011-01-31
DE602004029671D1 (de) 2010-12-02
CA2526530C (en) 2013-01-08
US20040242641A1 (en) 2004-12-02
JP4716999B2 (ja) 2011-07-06
TWI332502B (en) 2010-11-01
KR20120014235A (ko) 2012-02-16
EP1626973B1 (en) 2010-10-20
HK1092135A1 (en) 2007-02-02
ES2352199T3 (es) 2011-02-16
WO2004106342A1 (en) 2004-12-09
NZ543615A (en) 2009-04-30
MXPA05012738A (es) 2006-02-22
TW200510420A (en) 2005-03-16
PL1626973T3 (pl) 2011-04-29
EP1626973A1 (en) 2006-02-22
CN1826344A (zh) 2006-08-30
PT1626973E (pt) 2010-12-31

Similar Documents

Publication Publication Date Title
CY1111946T1 (el) To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
EP1470146B8 (en) Antibodies against the muc18 antigen
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2003057006A3 (en) Use of antibodies against the muc18 antigen
WO2005097119A3 (en) Pten inhibitors
DE602005023467D1 (de) (1s,5s)-3-(5,6-dichlorpyridin-3-yl)-3,6-diazabicycloä3.2.0üheptanbenzolsulfonat
ID29095A (id) Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
EE200200337A (et) Uued ühendid ning nende kasutamine
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
UY26426A1 (es) Nuevos compuestos
TW200616631A (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
SE9802209D0 (sv) Novel compounds
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
MY142646A (en) Chemokine receptor antagonists and methods of use therefor
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
EA200500538A1 (ru) Фармацевтическое средство для эндоназального применения при лечении болезней и нарушений нервной системы
UA2986U (uk) Спосіб лікування розсіяного склерозу